• Mashup Score: 137
    'We are ready to go': FDA OKs J&J and Legend's BCMA CAR-T, setting stage for showdown with Bristol Myers - 2 year(s) ago

    Move over, Bristol Myers Squibb. After delaying their decision by three months to review new information, the FDA has cleared Johnson & Johnson and Legend’s BCMA CAR-T rival cilta-cel, setting the stage for a showdown in multiple myeloma. Cilta-cel — which will be sold as Carvykti — marks the industry’s

    Source: Endpoints News
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of szusmani
      szusmani

      Cilta-cel gets the regulatory approval, great news for #mmsm patients! ⁦@JanssenUS⁩ ⁦@sloan_kettering⁩ ⁦⁦@IMFmyeloma⁩ ⁦@theMMRF⁩ ⁦@ASH_hematology⁩ ⁦@ASCO⁩ https://t.co/FEqXEpkDpz

    • Profile photo of SurbhiSidanaMD
      SurbhiSidanaMD

      Cilta-cel FDA approved for multiple myeloma! CARVYKTI, priced at $465,000, which is higher than ABECMA Exciting news for the myeloma community #mmsm #cartsm https://t.co/gaMxdsAjVT

    • Profile photo of Abdallah81MD
      Abdallah81MD

      'We are ready to go': FDA OKs J&J and Legend's BCMA CAR-T, setting stage for showdown with Bristol Myers - https://t.co/IeSEt52YpH #mmsm #myeloma #USMRC @kczmj @leshune @NausheenAhmedMD @aksinghmd @Haytham_Samy @KUcancercenter #MedTwitter

    • Profile photo of VincentRK
      VincentRK

      Awaiting more details on the label. But the first report I can find on the approval is here @Nicole_DeFeudis @endpts https://t.co/X8d4ErJOs6

    • Profile photo of CyclingDoctor
      CyclingDoctor

      Cilta-Cel approved for myeloma! #mmsm #bmtsm #celltherapy #cart @ManniMD1 @EagleMyeloma "FDA OKs J&J and Legend's BCMA CAR-T, setting stage for showdown with Bristol Myers" https://t.co/NWowlN348g

    • Profile photo of VincentRK
      VincentRK

      Breaking: FDA approves cilta cel for relapsed refractory myeloma. This is great news for myeloma patients. https://t.co/X8d4ErJOs6

    • Profile photo of JohnCendpts
      JohnCendpts

      Price is $465,000, higher than Abecma. https://t.co/UDWUMHFIOB

    • Profile photo of JohnCendpts
      JohnCendpts

      'We are ready to go': FDA OKs J&J and Legend's BCMA CAR-T, setting stage for showdown with Bristol Myers $JNJ $LEGN $BMY By @Nicole_DeFeudis https://t.co/UDWUMHFIOB

  • Mashup Score: 2
    Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse - 2 year(s) ago

    BackgroundDespite treatment with high-dose chemotherapy followed by autologous stem cell transplantation (AHCT), patients with multiple myeloma (MM) invariably relapse. Molecular residual disease (MRD)-negativity post-AHCT has emerged as an important prognostic marker predicting the duration of remission. Current techniques for MRD assessment involve bone marrow (BM) aspirate sampling, which is…

    Source: Frontiers
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Abdallah81MD
      Abdallah81MD

      My thoughts that ctDNA will be the future of how to change the treatment before relapsed MM and MRD testing in BMBx will go away: Using ctDNA to Identify Multiple Myeloma Patients at High Risk of Relapse https://t.co/gS0tVtB89d #mmsm #myeloma #USMRC #medtwitter #MedEd https://t.co/5DZmGqAWcm

  • Mashup Score: 2
    Genomic analysis of high-risk smoldering multiple myeloma - 2 year(s) ago

    Smoldering myeloma is an asymptomatic plasma cell dyscrasia with a heterogeneous propensity to progress to active myeloma. In order to investigate the biology of smoldering myeloma patients with high risk of progression, we analyzed the genomic characteristics …

    Source: PubMed Central (PMC)
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Abdallah81MD
      Abdallah81MD

      Genomic analysis of high-risk smoldering multiple myeloma https://t.co/fKNdAxnrcz #mmsm #myeloma #USMRC #MedEd #MedTwitter

Load More